TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00351624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DHA

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02887183

Intervention type: DRUG
Group type: OTHER
Intervention: LCZ696 (sacubitril/valsartan)
Description: LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
Study: NCT00765687

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: bisphosphates
Description: any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
Study: NCT01632293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance training
Description: The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
Study: NCT00818766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin or vancomycin
Description: Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
Study: NCT01540201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional I:E ratio
Description: conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I:E = 1:1 ratio
Description: I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
Study: NCT02918838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Own Adherence Group
Description: Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Adherence Group
Description: Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study: NCT00950183

Intervention type: DEVICE
Group type: OTHER
Intervention: Iceman® Cold Therapy unit (djOrtho)
Description: postoperative cold therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Ice
Description: postoperative cold therapy
Study: NCT03446560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP, conventional follow up
Description: Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP, telemedicine based follow up
Description: Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
Study: NCT02327520

Intervention type: OTHER
Intervention: Colitis with CDI treatment
Description: All patients will be treated with standard treatment
Study: NCT01913730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03249012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empiric use of Calcium Carbonate and Calcitriol
Description: Empiric calcium carbonate and calcitriol repletion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTH based Calcium Carbonate and Calcitriol repletion
Description: PTH based treatment
Study: NCT03777267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CR
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT02637297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Undergo hypnotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01552213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimum intervention control group
Description: A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment for glucose intolerance
Description: Diet, exercise glucose monitoring, insulin if necessary
Study: NCT00957502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTact™ Septal Stapler
Description: 1 year aged septal staples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTact™ Septal Stapler
Description: 18 Month Aged Staples
Study: NCT04272268

Intervention type: DEVICE
Intervention: Nasal High flow Oxygen
Description: If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
Study: NCT03987308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beinaglutide
Description: Five-week Beinaglutide pump treatment group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Five-week short-term CSII (insulin aspart) treatment group
Study: NCT01816594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
Study: NCT01203683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active computer-based training
Description: 8 sessions across 4 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert computer training
Description: 8 sessions across 4 weeks.
Study: NCT02248532

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy
Description: Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy
Description: Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
Study: NCT01830556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
Study: NCT03720756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nickel-free diet
Description: Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nickel-free diet
Description: Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
Study: NCT03101163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cells and hyaluronic acid
Description: Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Regimen of intra-articular HA injections and postoperative physiotherapy
Study: NCT02429154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnia
Description: Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)

Intervention type: OTHER
Group type: OTHER
Intervention: Mild Hypercapnia
Description: Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
Study: NCT03061760

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy due to prostate cancer.

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy due to prostate cancer.

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy due to prostate cancer.

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy due to prostate cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Initial evaluation
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation after 1,3,6,9,12 months
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation after 1,3,6,9,12 months
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation after 1,3,6,9,12 months
Description: Questioners, Ultrasound, Uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation after 1,3,6,9,12 months
Description: Questioners, Ultrasound, Uroflowmetry
Study: NCT01381900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Description: Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Description: Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulphonylurea
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
Study: NCT01405820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab IV
Description: natalizumab for IV Infusion
Study: NCT04486937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S410914 tablet
Description: S410914 tablet
Study: NCT03800199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation
Description: The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
Study: NCT03334240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS003
Description: CLS003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT04485325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: 5 mg twice daily, p.o.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg once per week, s.c.
Study: NCT04636775

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
Study: NCT00932308

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western-style diet (WD)
Description: Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prudent Diet (PD)
Description: Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
Study: NCT01080638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycoprotein IIb/IIIa inhibitor (abciximab)
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Study: NCT01816594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BKM120 Placebo
Description: Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
Study: NCT01643694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic intervention suggesting behavioral activity
Description: 3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
Study: NCT04363801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab 200mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200mg
Description: Administered by IV infusion
Study: NCT01080638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycoprotein IIb/IIIa inhibitor (abciximab)
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Study: NCT00114075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with gait analysis report
Description: Orthopaedic surgery with access to gait analysis report

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without gait analysis report
Description: Orthopaedic surgery without access to gait analysis report